Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
Nieves Martinez-ChanzaWanling XieMajd IssaHannah DzimitrowiczAbhishek TripathiBenoit BeuselinckElaine LamYousef ZakhariaRana MckaySumit ShahAmir MortazaviMichael R HarrisonSpyridon SiderisMarina D KaymakcalanSarah Abou AlaiwiAmin H NassarPier Vitale NuzzoAnis HamidToni K ChoueiriLauren C HarshmanPublished in: Journal for immunotherapy of cancer (2021)
Patients with RCC and UC with well-controlled AD can benefit from CPI with manageable toxicities that are consistent with what is expected of a non-AD population. Prospective study is warranted to comprehensively evaluate the benefits and safety of CPI in patients with AD.
Keyphrases